Table 2 Univariate and multivariate analysis for time to first therapy (TFT) in this series
From: MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
Univariate analysis | Multivariate analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Events | Total | Median | LCI | UCI | P | HR | LCI | UCI | P |
HSP9081 expression | ||||||||||
Normal | 12 | 39 | 104.0 | - | - | - | - | - | - | - |
High | 28 | 39 | 17.0 | 5.0 | 28.9 | 0.024 | 2.7 | 1.18 | 6.46 | 0.026 |
IGVH identity | ||||||||||
<98% | 15 | 60 | 104.0 | 11.3 | 196.7 | - | - | - | - | - |
≥98% | 39 | 57 | 14.0 | 6.8 | 21.2 | <0.001 | 2.34 | 1.03 | 5.35 | 0.043 |
Lymphocyte | ||||||||||
<30000 | 35 | 90 | 53.0 | 35.1 | 70.8 | - | - | - | - | - |
≥30000 | 25 | 37 | 8.0 | 0.0 | 17.5 | <0.001 | 4.2 | 1.75 | 10.05 | 0.001 |
Cytogenetics | ||||||||||
Good prognosis | 28 | 82 | 57.0 | 38.3 | 75.7 | - | - | - | - | - |
Poor prognosis | 16 | 21 | 9.0 | 1.7 | 16.2 | <0.001 | 1.65 | 1.907 | 2.54 | 0.023 |
Age (years) | ||||||||||
≥65 | 29 | 71 | 42.0 | 18.3 | 65.7 | - | - | - | - | - |
<65 | 29 | 53 | 24.0 | 6.6 | 41.4 | 0.04 | 0.37 | 0.17 | 0.83 | 0.015 |
B symptoms | ||||||||||
No | 42 | 194 | 49.0 | 34.3 | 63.7 | - | - | - | - | - |
Yes | 15 | 18 | 1.0 | 0.0 | 2.1 | <0..001 | 0.17 | 0.06 | 0.53 | 0.002 |